Form 8-K - 5/11/2007
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of The Securities Act of 1934
 
Date of Report (Date of earliest event reported):
May 11, 2007 

 
                          MERIDIAN BIOSCIENCE, INC.                            
(Exact name of Registrant as specified in its Charter)

 
                      Ohio                      
                    0-14902                      
        31-0888197         
(State or Other Jurisdiction of
         Incorporation)
(Commission File Number)
 (IRS Employer
Identification No.)

 
3471 River Hills Drive, Cincinnati, Ohio 
   45244    
(Address of Principal Executive Offices)
(Zip Code)

 
Registrant's telephone number, including area code
(513) 271-3700 


                                                                                                             
(Former name or former address, if changed since last report.)
 
 
        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


 
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


 
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


 
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.03.    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
On May 14, 2007, the Registrant filed an amendment (the “Amendment”) to its Amended and Restated Articles of Incorporation with the Secretary of State for the State of Ohio. The Amendment proportionately increased the Registrant’s authorized number of shares of Common Stock, without par value, from 50,000,000 to 71,000,000.
 
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 3 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 8.01.   Other Events.
 
On April 19, 2007, Meridian Bioscience, Inc. (the “Company”) announced that its Board of Directors had approved a 3-for-2 stock split of the Company’s outstanding shares of common stock (the “Common Stock”) effective May 11, 2007, for shareholders of record on May 4, 2007 (the “Stock Split”).
 
The Company is undertaking to meet the requirements of Rule 416(b) under the Securities Act of 1933, as amended, regarding the Registration Statements of the Company on Forms S-8 (File Nos. 333-122554 (2004 Equity Compensation Plan), 333-122002 (Savings and Investment Plan), 333-75312 (1999 Directors’ Stock Option Plan), 333-74825 (1999 Directors’ Stock Option Plan and 1996 Stock Option Plan), 333-18979 (1996 Stock Option Plan) and 033-65443 (1995 Savings and Investment Plan)) and Form S-3 (File No. 333-109139) (collectively, the “Registration Statements”). Under Rule 416(b), if additional securities are issued as a result of a stock split prior to the completion of the distribution of the securities covered by a registration statement, then the additional securities are covered by the registration statement, provided that the registration statement is amended. As discussed, the Company has effected the Stock Split. Pursuant to Rule 416(b), by virtue of this filing, the Registration Statements are deemed to cover the additional shares of common stock that may be sold as a result of the Stock Split.
 
In addition, the following tables present, adjusted to reflect the stock split, the Selected Financial Data from the Company’s Annual Report on Form 10-K for the year ended September 30, 2006 and earnings per share information for the interim periods in fiscal 2007:
 
Selected Financial Data - Annual Report on Form 10-K for the Fiscal Year Ended September 30, 2006
 
Amounts in thousands, except for per share data
 
Income Statement Information
 
 
     FY 2006     
FY 2005
    
FY 2004
    
FY 2003
    
FY 2002
  
Net sales
  
$
108,413
  
$
92,965
  
$
79,606
  
$
65,864
  
$
59,104
  
Gross profit
    
64,671
    
54,781
    
45,657
    
38,288
    
34,598
  
Operating income
    
26,881
    
20,216
    
14,658
    
12,789
    
9,994
  
Net earnings
   
18,325
    
12,565
    
9,185
    
7,018
    
5,031
  
Basic earnings per share
  
$
0.47
  
$
0.36
  
$
0.27
  
$
0.21
  
$
0.15
  
Diluted earnings per share
  
$
0.46
  
$
0.35
  
$
0.27
  
$
0.21
  
$
0.15
  
Cash dividends declared per share
  
$
0.28
  
$
0.20
  
$
0.17
  
$
0.15
  
$
0.12
  
Book value per share
  
$
2.42
  
$
2.15
  
$
0.98
  
$
0.83
  
$
0.74
  
 

 
Balance Sheet Information
 
   
30-Sep-06
  
30-Sep-05
  
30-Sep-04
  
30-Sep-03
  
30-Sep-02
  
Current assets
  
$
81,169
  
$
70,160
  
$
36,111
  
$
32,561
  
$
30,375
  
Current liabilities
    
20,617
    
19,791
    
16,650
    
15,330
    
15,249
  
Total assets
    
120,955
    
110,569
    
69,322
    
66,420
    
65,095
  
Long-term debt obligations
    
1,803
    
2,684
    
17,093
    
21,505
    
23,626
  
Shareholders' equity
    
94,777
    
83,768
    
32,932
    
27,484
    
24,381
  
 
Earnings Per Share and Cash Dividends Per Share Information - Interim Periods FY 2007
 
   
Three Months Ended
  
   
December 31, 2006
  
December 31, 2005
  
Basic EPS
  
$
0.14
  
$
0.10
  
Diluted EPS
  
$
0.14
  
$
0.10
  
Cash dividends
  
$
0.08
  
$
0.05
  
               
 
 
   
Three Months Ended
  
Six Months Ended
  
   
March 31, 2007
  
March 31, 2006
  
March 31, 2007
  
March 31, 2006
  
Basic EPS
  
$
0.15
  
$
0.12
  
$
0.29
  
$
0.22
  
Diluted EPS
  
$
0.15
  
$
0.12
  
$
0.28
  
$
0.22
  
Cash dividends
  
$
0.11
  
$
0.08
  
$
0.18
  
$
0.13
  
                           

Item 9.01.  Financial Statements and Exhibits.
 
(d)  Exhibits
 
 
3
Certificate of Amendment by the Board of Directors to the Amended Articles of Incorporation of Meridian Bioscience, Inc. dated as of May 4, 2007
 



 
SIGNATURES
 
 
        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  MERIDIAN BIOSCIENCE, INC.
 
 		  
 		  
 
Date:   May 11, 2007 By:   /s/ Melissa Lueke
 
Melissa Lueke
 
Vice President and Chief Financial Officer
(Principal Accounting Officer)